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Dendritic cells (DC) are critical regulators of both activation and tolerance in the adaptive
immune response. The dual nature of DC immunoregulatory function depends on their
differentiation and activation status. DC found within the tumor microenvironment (TME)
and tumor-draining lymph node often exist in an inactive state, which is thought to limit the
adaptive immune response elicited by the growing tumor. The major determinants of DC
activation and the functional alterations in DC that result from integrating exogenous stimuli
have been well investigated. Extensive efforts have been made to elucidate how the TME
contributes to the inactivated/dysfunctional phenotype of tumor-associated DC (TADC).
Although performed predominantly on in vitro DC cultures, recent evidence indicates that
DC undergo required, coordinated alterations in their metabolism upon activation, and
dysregulated metabolism in TADC is associated with their reduced immunostimulatory
capacity. In this review, we will focus on the role of glycolysis and fatty acid metabolism in
DC activation and function and discuss how these metabolic pathways may be regulated
in TADC. Further, we consider the need for developing novel experimental approaches to
assess metabolic choices in vivo, and the necessity for integrating metabolic regulation
into the optimized development of DC for tumor vaccines and immunotherapy for cancer.
Keywords: dendritic cell, tumor-associated dendritic cell, activation, metabolism, glycolysis, oxidative phosphory-
lation, lipid metabolism, cancer immunotherapy
INTRODUCTION
Dendritic cells (DC) serve as sentinels of the immune system.
They constantly acquire antigen (Ag) from their environment
and degrade it into short peptides that are presented at the cell
surface in association with MHC molecules for surveillance by
T cells. The inflammatory context in which DC exist influences
their expression of critical co-stimulatory molecules and cytokines
(Figure 1B) that provide the context for Ag presentation. Fac-
tors that promote the expression of co-stimulatory molecules
and cytokines support the activation, expansion, and survival of
responding T cells. In the absence of co-stimulation, DC present
Ag in a manner that induces tolerance in the specific T cell
repertoire, by mechanisms such as deletion (1) and anergy (2).
During infection, inflammatory cytokines such as TNFα and type-
1 interferons (IFN-1), or pathogen associated molecular patterns
(PAMPs), induce a program of activation that initiates the CCR7-
dependent migration of DC from the periphery to draining lymph
nodes (3, 4). Additional stimulation via CD40 can further raise the
activation state of DC, in part by inducing the expression of CD70
(Figure 1B) (5–7), leading to what is referred to as a licensed T cell
response. While these basic tenets of DC activation have been well
investigated, and extensively reviewed elsewhere (8, 9), recent stud-
ies have brought to light metabolic transitions in DC that are neces-
sary for them to attain full function,or can regulate their functional
activation. Here, we discuss the impact of these metabolic alter-
ations on DC function; how metabolic pathways may be regulated
in tumor-associated DC (TADC); and given the immature state of
DC often found in tumors [and the negative prognosis associated
with such immaturity (10, 11)] we consider the influence of the
tumor microenvironment (TME) on these functions.
REQUIREMENT FOR GLYCOLYSIS AND DC ACTIVATION
Substantial evidence demonstrates that upon activation immune
cells undergo a metabolic reprograming, switching from oxidative
phosphorylation (OXPHOS) to aerobic glycolysis, a phenomenon
initially observed in cancer cells in 1920s by Warburg (the Warburg
effect) (12). In cancer cells, the Warburg effect is induced by growth
factor signaling or by mutations in metabolism-related intrinsic
pathways [such as loss-of-function mutants of succinate dehydro-
genase (SDH) and Fumarate hydratase (FH), and constitutive acti-
vation of hypoxia-inducible factor-1 (HIF-1) and (c-Myc)] (13,
14), while T cells undergo the metabolic switch upon T cell recep-
tor (TCR) activation by Ag in the context of proper co-stimulation
(15). This change in cellular metabolic pathways provides essen-
tial metabolic and bio-energetic resources to support programs of
new gene expression and protein synthesis during robust cellular
proliferation. (16, 17)
A recent study from the Pearce group reported that PAMP
stimulation of TLR induces a metabolic transition in resting
immature DC, characterized by a conversion from mitochondrial
β-oxidation of lipid and OXPHOS (Figure 1A) to aerobic glycoly-
sis (Figure 1B) (18). Unlike in cancer cells and effector T cells, the
Warburg effect in DC does not fuel cell division but rather appears
to be crucial for DC activation and survival upon TLR stimulation.
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FIGURE 1 | Metabolic regulation of DC activation. Illustrated here are
metabolic pathways in resting DC (A) and activated DC (B). Upon TLR
stimulation, DC undergo a metabolic switch from OXPHOS (key mediators are
linked by black arrows) to glycolysis (key mediators are linked by blue arrows),
which contributes to their activation (major determinants in green; costim. is
short for co-stimulatory molecule). Block arrows mark blockade and dash lines
show insignificant process. The impact of mTOR on glycolysis has yet to be
fully elucidated in DC (see Section “AKT and mTOR in DC Function” in text).
During the early phase (within 5 h) after exposure to TLR agonists,
absence of glucose in culture medium led to profound defects in
DC activation, including surface expression of CD40 and CD86
and production of IL-12p40 (Figure 1B). Subsequently, DC acti-
vated by TLR signals are highly reliant on glucose for survival and
become more sensitive to death by nutrient limitation (18). Thus,
initiating glycolysis at the time of DC activation is critical for full
activation independent from its role in subsequent survival (18).
The glycolytic pathway, rather than OXPHOS, may be required
due to the need to generate substrates that will be used during
DC activation. Alternatively, components of the glycolytic path-
way, such as GAPDH, can directly regulate protein translation and
may be responsible for regulating the translation of proteins that
are critical for DC activation. Further studies will be necessary to
elucidate the mechanism by which glycolytic pathway promotes
the DC maturation process.
The induction of glycolysis and DC maturation could be influ-
enced by the tumor and the TME at several salient junctures
(Figure 2). First, in the context of tumors, it is unclear whether the
“find-me, eat-me”signals generated by damage associated molecu-
lar patterns (DAMPs)/alarmins, such as nucleotides, uric acid, heat
shock proteins (HSP), HMBG1, and calreticulin [which stimulate
DC in varied manners including via purinergic receptors (19),
CD91 (20), TLR engagement (21, 22), RAGE (23), and TIM-3
(24)], are sufficient to promote glycolysis and DC maturation in
the manner achieved with PAMP-mediated stimulation. Second,
tumor-derived DC, or DC cultured with tumors, have been shown
to be recalcitrant to TLR-mediated induction of CD40, CD86, and
IL-12 (25), suggesting that the induction of glycolysis via this path-
way in DC may be compromised. The mechanisms that regulate
TLR function in mature DC after exposure to tumors have yet to
be been elucidated, though inhibition of TLR signaling by MSR1
(see Section “MSR1 and DC Function” below) may contribute.
Third, tumors are highly competitive for glucose; thus the substrate
for glycolysis may be unavailable for DC and therefore the TME
may not be permissive for the aspects of DC activation that are
dependent upon glycolysis.
AKT AND mTOR IN DC FUNCTION
TLRs activate PI3K in a MyD88-dependent manner (26). Sim-
ilar to cancer cells (27, 28) and effector T cells (15, 29, 30),
PI3K/AKT pathway has been implicated to play a pivotal role in
controlling metabolic transition to glycolysis in TLR-stimulated
DC (Figure 1B) (18). AKT promotes glycolysis in DC in part by
increasing the expression of Glut-1 and likely activates mTOR.
In T cells, AKT signaling promotes glycolysis by inducing the
expression of rate-limiting enzymes such as hexokinase and phos-
phofructokinase (31) and activates mTOR. AKT is not the only
driver of metabolic alterations in TLR-stimulated DC, as it is
dispensable for the programed down-regulation of palmitate con-
sumption after TLR stimulation. (18). Confounding data exist,
however, about the contribution of mTOR (which is normally a
downstream target of AKT) to DC immunostimulatory capacity as
inhibition of mTOR by rapamycin in murine GM-CSF-driven DC
and human myeloid DC prolongs their lifespan, promotes expres-
sion of co-stimulatory molecules and cytokines, and enhances
DC immunogenicity (32, 33). Mouse DC treated with rapamycin
were more effective at generating tumor immunity compared to
untreated controls. (32). However, in contrast, rapamycin-treated
monocyte-derived human DC expressed significantly lower lev-
els of pro-inflammatory cytokines and had reduced capacity to
elicit CD8+ T cell responses (33). Thus, while the TLR-induced
activation of DC is dependent upon AKT-mediated induction of
glycolysis, the contribution of mTORC1 [which is required to
sustain glycolysis and effector functions in T cells (34)] to the
glycolytic switch is unresolved, and sustained mTORC1 activation
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FIGURE 2 | Influence of tumor-derived factors on metabolic
regulation of DC activation. Illustrated here are tumor-derived
factors (in red) and their impact/potential impact on metabolic
pathways (linked by red arrows) for DC activation. Other symbols are
defined the same way as in Figure 1. Lipid accumulation is
detrimental to DC activation by impairing Ag processing. How the TME
influences glycolytic switch and how that impacts DC activation
requires further investigation (see Sections “Requirement for
Glycolysis and DC Activation,” “Regulation of OXPHOS in DC,” and
“AMPK Regulation of DC Function”).
appears detrimental to the function of DC. Further studies are
also needed to dissect the contribution of mTORC2 to any of
these processes.
REGULATION OF OXPHOS IN DC
The underlying mechanisms for the AKT-independent reduction
in OXPHOS upon TLR stimulation of DC have been recently
studied using real-time metabolic flux analysis (35). The progres-
sive impairment in OXPHOS in TLR-stimulated DC is due to
inducible nitric oxide synthase (iNOS)-derived NO (Figure 1B).
LPS stimulation induces NOS2 mRNA and iNOS protein expres-
sion, and subsequent NO production in DC, presumably via IFN-1
or NF-κB-dependent mechanisms as reported in macrophages
(36). The autocrine NO causes mitochondrial impairment and
blocks OXPHOS, as reported previously in astrocytes (37) and
macrophages (38). The mechanism of OXPHOS inhibition is likely
by NO reversibly competing with oxygen to inhibit cytochrome
c oxidase, the terminal enzyme of the electron transport chain
(39). Thus, the increase in glycolysis in DC after TLR stimulation
could be a survival response that serves to maintain cellular
ATP levels and to prevent cell death when OXPHOS is blocked
and pyruvate accumulates. Most interestingly, although switch
to glycolysis has been demonstrated to be a direct consequence
of iNOS-mediated OXPHOS blockade and is essential for the
survival of iNOS-expressing DC in vivo, a long-term switch to
glycolysis was shown to be dispensable for full DC activation.
When NO production is inhibited, glycolysis is abrogated and β-
oxidation is maintained in TLR-stimulated DC. Despite this, these
DC showed unimpaired if not enhanced activation, as assessed
by surface expression of MHC and co-stimulatory molecules,
production of inflammatory cytokines, and capacity of DC to
stimulate T cell proliferative responses at 24 h after TLR stimula-
tion. Therefore, optimal DC function may require only a transient
switch to glycolysis; this notion is consistent with the fact that
either stimulation of CD40 (see below) or limiting mTOR activity
promotes DC function, and raises an alternative hypothesis to
explain DC dysfunction in tumors: that rather than being unre-
sponsive to DAMPs, chronic exposure to DAMPS from tumors
leads to a state of glycolysis-induced exhaustion or elimination of
DC (Figure 2).
AMPK REGULATION OF DC FUNCTION
The switch to glycolysis by DC is antagonized by adenosine
monophosphate–activated protein kinase (AMPK), a master reg-
ulator of catabolic metabolism/OXPHOS in eukaryotic cells
(Figure 1) (40, 41). AMPK can be induced by the nutrient sensor
LKB1 (42), and functions in an opposing fashion with PI3K/AKT
pathway to regulate TLR-induced metabolism and DC activation
(Figure 2): up-regulation of AMPK in DC resulted in decreased
LPS-induced IL-12p40 expression and glucose consumption,
while suppression of AMPK by shRNAi leads to increased IL-12p40
and CD86 (18). Given the capacity of tumors to compete for glu-
cose, one possible explanation for limited DC activity within the
TME is the dominance of AMPK signaling over AKT-driven path-
ways (Figure 2). Intriguingly, IL-10, an inhibitor of DC activation,
has been found to antagonize the TLR-induced hypophosphory-
lation of AMPK in TLR-stimulated DC, subsequently inhibiting
the induction of glycolysis (18). AMPK activity is also strongly
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induced by cAMP (Figure 2). Along with adenosine, cAMP can
skew myeloid cell differentiation to a tolerogenic DC format (43,
44) and ablate the function of already differentiated DC (45). It
is therefore intriguing to consider whether the negative regulatory
activity of cAMP and adenosine in tumor immunity is mediated
by abrogating glycolysis. However, the increased immunostimu-
latory capacity of DC after mTOR blockade or iNOS inhibition
is not simply due to a restoration of β-oxidation. If this were
the case, then contrary to these observations, AMPK activation
should promote DC immunostimulatory capacity. Further, liga-
tion of CD40, which signals via TRAF-6, has a major influence on
DC activation state and viability (46–49), and is a potent promoter
of co-stimulatory molecule and IL-12 expression and immunity
to cancer. TRAF-6 mediated signaling has been shown to pro-
mote fatty acid oxidation in CD8+ T cells (50) via activation of
AMPK, raising the question as to how signals generated by CD40
engagement might be integrated into the metabolic programing
initiated by TLR signaling. AMPK agonists have been proposed as
anti-cancer agents due to their anti-Warburg effect in cancer cells
(51), but this approach may be compromised by the detrimental
effects of AMPK on DC and CD8+ T cell function. The role of
AMPK in regulating glycolysis and β-oxidation in early and late
stages of DC function requires further elucidation before it can be
predicted how such an approach would impact on DC function in
tumors.
LACTIC ACID REGULATION OF DC FUNCTION
Additional metabolic regulation of DC has been described.
Endogenously produced lactic acid, the end product of glycol-
ysis, accumulates in dense monocyte-derived DC cultures and
tumor spheroids (52). Lactic acid concentration after glycolysis,
rather than oxygen availability, skews DC differentiation into a
tolerogenic orientation, as exemplified by increased production
of IL-10 and loss of IL-12 (Figure 2) in response to TLR stimuli
(53). This potentially identifies a negative feedback loop in DC
function induced by glycolysis within activated DC, and may sug-
gest that the beneficial effect of preventing the switch to glycolysis
achieved by inhibiting NO production in vitro (35) could be a sec-
ondary consequence of avoiding lactic acid accumulation in DC
culture. Interestingly, Ag uptake, MHC class I presentation and co-
stimulatory molecule (CD40 and CD86) expression on DC can
be increased by acidosis/extracellular acid (54), via acid-sensing
ion channels (ASICs) (55). Thus, acidity and lactate accumulation
may be independent variables on DC maturation. Although lactic
acid buildup due to excessive DC density is unlikely to be a major
consideration in vivo, tumor-generated lactic acid may serve this
purpose (Figure 2) (27, 56, 57). Lactate export by cells is passive,
mediated by monocarboxylate transporters (MCTs). A high extra-
cellular lactate concentration in the TME could prevent its export
from glycolytic DC, leading to lactate accumulation. It is also worth
considering whether lactic acid buildup will differentially affect
DC that are resident within tumors compared to those at the tumor
edge, and whether lymph node resident DC are vulnerable to lactic
acid prior to lymph node invasion by metastatic disease. Further
investigations are necessary to establish a comprehensive under-
standing about how changes in glycolysis and OXPHOS influence
activation and/or survival of different TADC subsets, whether DC
maturation states are equivalently influenced by metabolic alter-
ations, and whether diverse TLR and other PAMP stimuli have
similar impact on DC metabolism.
LIPID UPTAKE AND METABOLISM IN TADC
While a switch to glycolytic metabolism is generally consistent with
immune cell activation, fatty acid metabolism, and lipogenesis are
thought to promote quiescence (17, 50). Several studies have now
begun to illuminate a rather complex role of lipid, and lipid accu-
mulation, in DC function, and how the presence or production of
triglycerides (triacylglycerol, TAG) in the context of tumors may
influence DC function.
As DC develop and mature, particularly after LPS stimulation,
they take on a “lacy” appearance that is composed of an increased
presence of fat and glycogen-containing lipid-body droplets (58).
Notably, these high lipid DC (HL-DC) express higher levels of
scavenger receptors including MARCO/MSR1, which may con-
tribute to their accumulation of lipid (58). Aside from serving as
a building block for many facets of DC biology, lipid can con-
tribute to critical aspects of the ability of DC to perform their
Ag processing and presentation functions. Cross-presentation of
exogenous Ag on MHC class I molecules is highly dependent upon
the presence of lipid bodies. Genetic inactivation of genes that
regulate lipid-body assembly, or the use of diacylglycerol acyl-
transferase inhibitors that prevent TAG accumulation, abrogates
the MHC class I cross-presenting capability of DC (59). Thus, lipid
production and consumption play critical roles in DC biology.
LIPID-MEDIATED INHIBITION OF TADC FUNCTION
It is therefore of interest that elevated levels of lipid, partic-
ularly TAG, were observed first by Herber and colleagues in
DC during tumor progression of lymphoma, colon, and breast
cancer in preclinical mouse models and cancer patients (60). The
observed increased lipid accumulation is primarily a consequence
of increased lipid uptake via up-regulated scavenger receptor A
(SRA/MSR1/CD204) (Figure 2). Remarkably, considering the data
from Bourgneres et al. (59), the major functional defect in HL-DC
was a reduced capacity of DC to cross-present Ag (60). Normaliza-
tion of lipid levels by a pharmacological inhibitor of acetyl-CoA
carboxylase-1 (ACC-1), an enzyme that plays a critical role in lipo-
genesis, restored functional activity of lipid-laden DC, and enabled
them to become more potent when used in a cancer vaccine (60).
There are several notable aspects of this study that are worthy of
further consideration. First, as mentioned above, lipid in DC by
itself is not necessarily a marker of dysfunction. Indeed, a recent
study examined the immunogenic qualities of liver-derived DC
containing high and low amounts of lipid. HL-DC were consider-
ably more immunogenic than their low lipid counterparts across
multiple measurements (61). Further, Hwang and colleagues have
demonstrated that saturated fatty acids can activate TLR4, lead-
ing to the up-regulation of MHC and costimulatory molecules. In
contrast, polyunsaturated fats such as DHA, counteract the ability
of saturated fats to induce DC maturation (62). Thus, rather than
the amount of lipid within a DC being detrimental to function,
the process by which lipid is acquired, or synthesized, or the type
of lipid (saturated versus unsaturated) may be influential on DC
function.
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MSR1 AND DC FUNCTION
MSR1 has been shown to act both as a lipid receptor and
as an innate pattern recognition receptor (PRR) that regulates
inflammatory responses. As the first receptor identified for mod-
ified lipoproteins, the role of MSR1 has been well explored in
pathogenesis of vascular disease particularly atherosclerosis (63).
Besides modified self macromolecules, a wide range of PAMPs
have been identified as MSR1 ligands, including bacterial sur-
face components (e.g., LPS) and nucleic acids (e.g., CpG DNA
and double-strand RNA), apoptotic cells, and endogenous danger
molecules (64). Notably, the first report about negative effects of
MSR1 in DC activation and function during adaptive immunity
was presented by Yi and colleagues (65), in which they demon-
strated that MSR1 suppresses the ability of TLR4 stimulation to
license DC to prime naive CD8 T cells, drive their expansion, and
promote their cytotoxic functionality both in vitro and in vivo (65).
In agreement with data from Herber et al. they showed that lack of
MSR1 in hematopoietic cells promoted tumor-protective immu-
nity in a B16-OVA mouse melanoma model. In this model, MSR1
suppressed TLR4-induced activation of the transcription factor
NF-κB by directly inhibiting ubiquitination of TRAF-6 (Figure 2)
(66). However, the restriction of NF-κB activity by MSR1 can
be independent of its ligand-binding domain, implying a novel
signaling-regulatory role of MSR1 that can be uncoupled from its
conventional role in endocytosis, including lipid uptake. Accord-
ingly, one can speculate that up-regulation of MSR1 can contribute
to DC dysfunction in cancer by skewing at least two pathways: (1)
accumulation of lipids (2) suppression of TLR signaling. With
respect to the second point, inhibition of TLR signaling may alter
the balance between lipolysis and lipogenesis in favor of lipid accu-
mulation. The therapeutic relevance of MSR1 and lipid uptake
is reinforced by studies showing that direct targeting of MSR1
promotes tumor immunity (67, 68). Further, recent studies by
Lerret et al. showed that the ability of total body irradiation (TBI),
in combination with adoptive transfer of tumor-specific CD8+
T cells, to control established breast tumors may be achieved
by promoting activation and function in tumor-resident DC via
down-regulating MSR1 and inhibition of lipid uptake (69, 70).
However, the tumor-derived factors that up-regulate MSR1 are
poorly characterized, and it is yet to be definitively shown that
lipid is an immunoregulatory ligand for MSR1on DC.
MSR1-INDEPENDENT EFFECTS OF LIPID ON TADC
Although MSR1 engagement could account for poor DC function,
additional influences of lipid on DC cannot be ruled out. Inhibi-
tion of ACC-1 resulted in normalization of lipid levels in TADC
and was sufficient to restore functional activity in lipid-laden DC
without changing expression of MHC and costimulatory mole-
cules (60). This indicates that at least some accumulation of lipid
in DC is due to de novo lipogenesis (Figure 2). Further, either
the detrimental effects of lipid accumulation can be independent
of MSR1 (as ACC-1 inhibition refunctionalizes TADC), or path-
ways released by ACC-1 inhibition can overcome MSR1-mediated
inhibition. Evidence for the latter concept has been provide by
Rehman et al. in a study demonstrating that ACC-1 inhibition
enhances Ag capture (rather than Ag processing) by human DC
(71). Confounding our understanding is that ACC-1 regulates the
production of malonyl CoA, which in turn inhibits the activity
of Carnitine palmitoyltransferase Ia (Cpt1a) (Figure 1A). Cpt1a
strongly suppresses glycolysis via the Randle cycle, and knockdown
of Cpt1a has been shown to strongly promote glycolysis in T cells
(72). Thus, it is unclear why the inhibition of ACC-1, which should
reduce glycolysis, enhances DC function unless (1) the lipogene-
sis program activates pathways that are significantly deleterious
to DC function; (2) sustained glycolysis is indeed detrimental to
DC function (discussed above); or (3) the presence of lipid is
the detrimental factor, by influencing the availability of pyruvate
for glycolysis rather than OXPHOS (73). Pointedly, it is uncer-
tain why the accumulation of lipid might be detrimental to DC
function at the level of Ag processing and presentation, especially
given the importance of lipid bodies in this process. However, it
has been shown that ceramides, which due to their hydrophobic-
ity could accumulate in fat droplets, abrogate the ability of DC to
uptake and present Ag (74) and also promote tumor-induced DC
apoptosis (75).
IN VITRO VERITAS?
While the emerging picture of how alterations in DC metabolism
can influence the function of DC, several words of caution should
be written. One noticeable aspect of the majority of the studies
cited in this review is that analysis of the contribution of meta-
bolic alterations to DC function has generally been performed
on DC generated from bone marrow or PBMC. This is necessi-
tated by the rarity of DC in tissues, and the low sensitivity of the
assays that are currently available to characterize metabolic activ-
ity. Thus, it is possible to posit that some metabolism-associated
alterations described in these studies could be dependent upon
the culture conditions that generate or sustain DC, and extrap-
olation to in vivo DC, particular to intratumoral DC, is not yet
merited. DC, particular those of murine origin, generated via cul-
ture exist in a semi-activated functional state (our unpublished
data) that may lead to different metabolic choices, and be influ-
enced by different stimuli, compared to truly immature DC. This
point is particularly salient when we consider some of the reported
discrepancies on the impact of limiting or promoting glycolysis by
modulating mTOR activity. Further, much work has yet to be done
in defining whether metabolic alterations actually promote dis-
crete functions of DC,or whether metabolic switching is a response
to alterations in the nutrients in the immediate environment of the
DC (tissue; lymphatics; lymph nodes, for example). However, the
capacity for TLR to induce metabolic changes in DC in the con-
sistent nutrient environment provided by in vitro culture, suggests
that metabolic changes are not entirely due to alterations in the
available nutrients, but rather these metabolic changes directly
impact/regulate the activation and survival of DC. The single-cell
analytical luxuries provided by flow cytometry have yet to be trans-
lated to metabolism studies, limiting our ability to make direct
assessment of in vivo DC metabolic changes. Unfortunately, until
radiotracer incorporation, extracellular flux assays, and mass spec-
trometry can be applied to 1000s of cells, rather than 100,000s, we
will be dependent upon the use of fluorochrome-labeled substrates
such as the glucose-derivative 2-NBDG to guide our impression of
the metabolic pathways being used by DC derived from different
in vivo environments.
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SUMMARY
The metabolic and biochemical regulation of DC activation, func-
tion, and survival are just the beginning to be elucidated. Further
understanding of this process will likely improve the quality and
efficacy of DC expanded ex vivo for cancer vaccines [note the
varied influences of cytokines on vaccine efficacy (9, 76)], as
cytokines are known to impact metabolism. Further, metabolic
re-invigoration of DC may provide an avenue for enhancing DC
function in the TME or in tumor-draining lymph nodes, allowing
for increased Ag processing and presentation after the induction
of tumor damage, or in association with inhibition of checkpoint
blockade molecules. Finally, approaches that promote the avail-
ability of glucose, or limit lipid uptake, in the TME might well
increase the ability of TADC to activate and contribute to the
adaptive immune responses elicited against tumors.
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